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Previous studies have established that a subset of head and neck
tumors contains human papillomavirus (HPV) sequences and that
HPV-driven head and neck cancers display distinct biological and
clinical features. HPV is known to drive cancer by the actions of the
E6 and E7 oncoproteins, but the molecular architecture of HPV
infection and its interaction with the host genome in head and
neck cancers have not been comprehensively described. We pro-
filed a cohort of 279 head and neck cancers with next generation
RNA and DNA sequencing and show that 35 (12.5%) tumors
displayed evidence of high-risk HPV types 16, 33, or 35. Twenty-
five cases had integration of the viral genome into one or more
locations in the human genome with statistical enrichment for genic
regions. Integrations had a marked impact on the human genome
and were associated with alterations in DNA copy number, mRNA
transcript abundance and splicing, and both inter- and intrachro-
mosomal rearrangements. Many of these events involved genes
with documented roles in cancer. Cancers with integrated vs.
nonintegrated HPV displayed different patterns of DNA methyla-
tion and both human and viral gene expressions. Together, these
data provide insight into the mechanisms by which HPV interacts
with the human genome beyond expression of viral oncoproteins
and suggest that specific integration events are an integral
component of viral oncogenesis.
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Head and neck cancer (HNC) is a heterogeneous group oftumors characterized by a common anatomic origin, and
most such tumors develop from within the mucosa and are
classified as head and neck squamous cell carcinomas (HNSCCs)
(1). HNSCC, the sixth most common cancer diagnosed world-
wide and the eighth most common cause of cancer death (2), is
frequently associated with human papillomavirus (HPV) infection
(3, 4). Depending on the anatomic site of the tumor, HPV prev-
alence is estimated at 23–36% (5). HPV-positive HNSCCs form
a distinct subset of HNCs that differs from HPV-negative HNSCCs
in tumor biology and clinical characteristics, including superior
clinical outcomes (6–9).
The molecular pathogenesis of HPV-driven HNSCC also seems
distinct from HPV-negative tumors, with previous studies showing
a divergent spectrum of alterations in gene expression, muta-
tions, amplifications, and deletions as well as distinct epigenome
alterations (10–15). HPV is known to drive tumorigenesis
through the actions of its major oncoproteins E6 and E7, which
target numerous cellular pathways, including inactivation of p53
and the retinoblastoma (Rb) protein (16–18). Together with E5,
they also play an important role in immune evasion, being involved
in both innate and adaptive immunity (19, 20).
Initially after infection, HPV is identified in circular extra-
chromosomal particles or episomes. A critical step in progression
to cancer is the integration of viral DNA into the host cell
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genome (21). Integration breakpoints often occur in the HPV
early genes E1 or E2, disrupting their expression, which leads to
the deregulation of negative feedback control of E6 and E7
oncogene expression by the viral regulatory E2 protein. Inte-
grant-derived transcripts are more stable than those derived
from episomal viral DNA, and HPV integration has been asso-
ciated with increased proliferative capacity and selective growth
advantage for the affected cells (6, 22). Another crucial event
frequently associated with HPV integration is genomic instability
of the infected cells (23).
The physical state of the virus and its interaction with the host
genome in HPV-associated tumors has been well-characterized
in cervical cancer (24–30), but less is known about the molecular
architecture of HPV infection in HNC (31, 32). Recently,
a comprehensive genome-wide analysis of HPV integration in
human cancers showed associations between HPV integrants and
extensive host genomic amplifications and rearrangements, in-
cluding deletions, inversions, and chromosomal translocations (12).
However, the study primarily used HNSCC cell lines and included
only two primary HNCs. There is still a lack of comprehensive
analyses of primary HNSCCs using a multiplatform approach, in
which integrations are characterized in the context of changes in
the DNA, RNA, and epigenome at the site of integration.
Here, by analysis of 35 primary HPV-positive HNCs with whole-
genome, transcriptome, and methylation profiling, we describe
genomic changes, including massive structural variations, differ-
ential DNA methylation and expression patterns, that occur in
HPV-positive primary head and neck tumors and are associated
with viral integrations.
Results
Characterization of HPV Integrations. Using the dataset of 279
HNSCCs developed by The Cancer Genome Atlas, we performed
computational subtraction (33) and quantitative assessment of
HPV E6 transcripts and identified 35 tumors with evidence of
HPV DNA and RNA sequences. HPV16 was the most common
type, and it was detected in 29 of 35 tumors, with the remaining
cases having either HPV33 or HPV35. Based on single-nucleotide
variants present in HPV16 sequences (Dataset S1, Table S1), we
assessed the variant lineage and sublineage in each case. The
variant lineages and sublineages of 29 HPV16-positive samples
were 22 European, 3 African 1, 2 Asian, 1 African 2, and 1 Asian
American. Demographic data and clinical characteristics of these
patients are presented in Dataset S1, Table S2.
To gain insight into the interaction of HPV with the host ge-
nome, we determined if the HPV genome was integrated into the
tumor genome using whole-genome sequencing (WGS; 6–8× or
30–60× target coverage) together with RNA sequencing. We
considered the viral genome integrated if there were at least
three discordant pairs (in which one end of the paired end read
mapped to the viral genome, and its mate pair mapped to human
genome) and one split read (in which one end of the paired end
read spanned the junction, and its mate pair mapped to either
the human or HPV genome), and these seven total reads sup-
ported integration at the same locus. Such criteria allow for
detection of integrations present in a single copy per cell with
6–8× coverage WGS if the majority of tumor cells in the sample
derived from the clone containing integration, although higher
coverage may be needed to detect subclonal integration events,
the pathologic significance of which is unclear. Of 35 cases ex-
amined, 25 cases had integration of the viral genome into 1–16
regions in the human genome, with 103 breakpoints in total
(Fig. 1 and Dataset S1, Table S2). The presence of reads span-
ning the insertion site allowed us to determine the sites of in-
tegration with single-nucleotide precision. Of more than one-half
of integration breakpoints, 60% occurred in regions of micro-
homology (1–10 bp) among the viral and human genomes and
were nonrandom given that, in all cases but one, integration left
at least HPV E6 or E7 intact.
Of 103 integration events, we found that, in 56 (54%) cases,
the virus integrated into a known gene, and in 19 (17%) cases,
integration occurred within 20 kb of a gene, suggesting a selec-
tive pressure for viral integration into or near genes (P = 0.0029).
We also noted a spatial correlation among HPV breakpoints and
miRNAs (P = 0.0015). Viral integration was associated with
increases in somatic DNA copy number of the integrated region;
84 (82%) HPV breakpoints colocalized with somatic copy num-
ber variants (CNVs; P < 0.0001), and the rest were at least 1 Mb
from a CNV. Some colocalized CNVs were amplification events
seeming to result from excision of the integrated virus along with
human sequences with subsequent circularization, suggestive of
maintenance as an episome containing the viral replication origin.
Tumors with HPV integration displayed a nonsignificant trend
toward a higher mutational burden (Fig. S1B).
In an exploratory analysis, we correlated the presence or absence
of HPV integration in the host genome with expression of HPV
genes and several clinical variables, including anatomic site of tu-
mor, tumor stage (TNM), age, and smoking status of the subject.
No statistically significant correlations among HPV integration and
these clinical variables were identified in this relatively small
dataset (Fig. S1C). Furthermore, there was no statistical associa-
tion of HPV integration status with clinical outcome (Fig. S1A).
Integration-negative tumors displayed a trend toward higher levels
of HPV E2/E5 expression and lower levels of E6/E7 expression
compared with integration-positive tumors (Fig. S2A) (P = 0.002,
P = 0.05, P = 0.002, and P = 0.004, respectively). We did not
Fig. 1. Distribution of integration sites across HPV genome and human genome. Integration breakpoints are shown for the HPV16-positive tumors. Two
breakpoints involving human GL000220.1 are excluded. Breakpoint colors correspond to HPV genes where integration event occurred. The HPV genome
scheme includes early and late genes, the viral origin of replication ori, the early viral promoter (p97), and the late differentiation-dependent promoter (p670).











observe a correlation among the presence of integration within
specific HPV genes and their expression level. One possible
reason for this lack of correlation is the presence of intact copies
of HPV genome in the same samples.
HPV Integrations Are Associated with Somatic Alterations of Key
Cancer Genes. Because the genomic localization of viral in-
tegration appeared nonrandom, we hypothesized that the in-
tegration events had an impact on cancer development. Detailed
analysis of the genes and the insertion sites revealed several
distinct possible mechanisms by which the viral insertion may
confer a selective advantage. One case involved integration of
the viral genome into the DNA repair protein RAD51 homolog 2
(RAD51B) gene on chromosome 14 (Fig. 2). In this tumor, we
identified three viral integration breakpoints within this gene,
disrupting the E1, E4, or E5 genes of the virus. All three in-
tegration events occurred within intron 8 of the gene. After in-
tegration, a 42-kb segment of intron 8 and the viral genome
amplified to 28-fold, consistent with the possibility that this
amplified chimeric segment is episomal. Extrachromosomal lo-
cation of the amplified RAD51B region was supported by FISH
analysis (Fig. S3). Examination of RNA expression data revealed
that transcripts corresponding to exons 9–11 and 13 of RAD51B
were significantly elevated, generating alternative transcripts that
were unlikely to produce a functional RAD51B protein. RAD51B
is an important component of the DNA double-strand break re-
pair pathway, and loss-of-function variants in this gene have been
reported in uterine leiomyoma and breast cancer (34).
A second mechanism by which the viral insertion may be in-
volved in tumor development is illustrated by the insertion of
HPV16 into the v-ets avian erythroblastosis virus E26 oncogene
homolog 2 (ETS2) gene on chromosome 21 (Fig. S4A). In this
case, the integration resulted in the replacement of exons 7 and 8
of the ETS2 gene by HPV 16. The second copy of the ETS2 gene
appeared intact. RNA expression data revealed that the overall
level of expression of ETS2 was unchanged in this tumor, al-
though the levels of exons 7 and 8 were markedly reduced,
suggesting that exon skipping occurs as a result of viral in-
tegration. ETS2 is a tumor suppressor gene (35), and previous
reports have shown that truncated ETS family proteins may act
in a dominant negative fashion (36). Our findings suggest that
insertion of viral sequences into one of two copies could result
in the loss of function of this gene. A similar effect of HPV in-
tegration was seen in the case of the CD274 [programmed death
ligand 1 (PDL1)] gene on chromosome 9 (Fig. S5). In this case,
the virus integrated into an intron flanked by exons 4 and 5, and
expression levels of exons 5–7 were attenuated, suggesting that
viral integration into this locus resulted in an altered form of PDL1
that is expressed at high levels. Alternative PDL1 transcripts have
been reported (37, 38) and associated with poor prognosis in renal
cell carcinoma (37).
A third mechanism was illustrated by integration of HPV
30 kb upstream of the nuclear receptor subfamily 4, group A,
member 2 (NR4A2) gene (Fig. S4B). The insertion was followed
by 248-fold amplification of a 75-kb genomic region including
the entire NR4A2 gene. RNA-sequencing (RNA-seq) analysis
revealed that the level of expression of the NR4A2 gene was
significantly elevated (Fig. S4B). NR4A2 is a member of the
nuclear transcription factor gene family and has been reported
as an oncogene (39, 40). Our results suggest that the HPV in-
tegration in this sample and subsequent amplification resulted in
overexpression of the NR4A2 oncogene. RNA-seq analysis of
HPV expression showed low levels of E6 and E7 transcripts in
this tumor (Fig. S2A), suggesting that this integration event may
Fig. 2. Integrated analysis of HPV integration events. Breakpoint locations and joining patterns are shown with regard to schematic representations of the
HPV and human genomes, regions of copy number alteration, and exon expression of genes involved and/or located near integration sites. Colored regions
on the genome schemes represent sequences included in the integrated structure. Gray regions represent sequences that were replaced or lost as a result of
integration. RAD51B integration leads to 28-fold amplification of the intronic region and overexpression of exons located downstream of the integrated
virus. The integrated HPV genome retained oncogenes E6 and E7 (both promoters and ori).
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be of greater importance in this tumor than the impact of the
HPV oncoproteins.
A fourth example is represented by HPV insertion in the region
of an interchromosomal translocation between chromosomes
3 and 13. HPV was integrated in a nongenic region, but the
rearranged region contained the tumor protein p63 regulated 1
(TPRG1) and tumor protein p63 (TP63) loci on chromosome 3
and the Kruppel-like factor 5 (KLF5) gene on chromosome 13
(Fig. S4C). The integration occurred near the KLF5 promoter
and about 150 bp downstream of the translocation junction.
Genomic regions involved in this complex event were ampli-
fied. RNA-seq data showed increased levels of expression of
KLF5, TP63, and TPRG1. KLF5 (41) and TP63 are transcrip-
tion factors known to regulate cellular proliferation and tumor
formation, and TP63 has a documented role in the pathogen-
esis of squamous cell carcinomas (11, 42). Our results suggest
that viral integration was associated with a structural rear-
rangement and that these events resulted in the overexpression
of these oncogenes.
HPV Integration Is Associated with a Specific Methylation Signature.
Previous work has shown that HPV-positive tumors have a dis-
tinct methylation profile compared with HPV-negative tumors
(43, 44). To study the influence of HPV integration events on the
host cell, we compared the patterns of DNA methylation and
gene expression of HNSCCs with and without integration. Using
a linear model of differential methylation and expression for
each cytosine-phosphate-guanine (CpG) locus and mRNA, re-
spectively, we found subsets of genes with significantly distinct
patterns of methylation and expression among tumors with and
without integrated HPV (Fig. 3 and Dataset S1, Tables S3 and
S4). Unsupervised clustering of these subsets (Fig. S6) for all
studied tumors and adjacent normal tissue controls revealed that
the patterns of DNA methylation and gene expression profiles of
integration-positive tumors are similar to those of HPV-negative
tumors and normal tissue, whereas integration-negative tumors
differed from the other three groups. There were no associations
of distinct methylation patterns with clinical variables, with the
exception of weak correlations with tumor site (P = 0.038) and E7
expression (P = 0.045) (Fig. S7B).
Four genes among those found in both differentially methylated
and expressed subsets are of particular interest. Suppressors of
tumor progression BARX2, which encodes a homeobox transcrip-
tion factor, and IRX4, a homeodomain-containing transcription
factor of the Iroquois family (45, 46), were hypermethylated and
underexpressed in the integration-negative tumors (Fig. S8 A and
B). Conversely, a single-minded family bHLH transcription factor
2 (SIM2) and an intracellular proteinase CTSE, both known to be
associated with tumorigenesis and cancer progression (47, 48),
displayed hypomethylation and increased expression in integration-
negative tumors (Fig. S8 C and D). Recent studies have reported
hypermethylation and inversely correlated expression of IRX4 in
HPV-driven oropharyngeal tumors compared with non–HPV-
driven tumors, and the hypermethylation signature correlated
with better clinical outcomes (49). Using Gene Set Enrichment
Analysis, we observed differential methylation of genes in the
cAMP response element-binding protein (CREB) pathway and
differential expression of genes involved in regulation of apo-
ptosis and NF-κB signaling. These data suggest that the biology
of HPV-integrated vs. nonintegrated HNCs may be distinct and
that HPV may drive changes in cellular gene expression when
HPV presents in the episomal form.
Fig. 3. DNA methylation and gene expression analysis. (A and B) Heat map
of DNAmethylation levels for significantly differentially methylated CpG loci
and mRNA expression of significantly differentially expressed genes (rows)
for all HPV-positive samples (columns).The columns of the heat maps are
organized by HPV integration status: samples with and without virus in-
tegration are marked at the top of the heat maps in green and blue, re-
spectively. (C) Scatter plot of averaged significantly differential methylation
and expression values. One HPV(+)/integration(−) sample did not have RNA-
seq data and is not represented on the expression heat map and scatter plot.












Here, we show by WGS, transcriptome, and DNA methylation
analyses of 35 HPV-associated HNCs that HPV is present in
both integrated and nonintegrated forms in these cancers. We
show that, in addition to viral E6 and E7 expression, HPV is
likely to drive tumorigenesis by alteration of the host genome at
sites of integration. Mechanisms by which integration affects host
genes include generation of altered transcripts, disruption of
tumor suppressor genes, high-level DNA amplifications, and
interchromosomal rearrangements. Such mechanisms revealed
for primary tumors are in agreement with those observed by
Akagi et al. (12) in their study of HNC cell lines.
It is noteworthy that not all tumors with integrated HPV
showed enhanced expression of viral E6 and E7 oncoproteins. In
fact, at least seven samples in which viral integration occurred
showed an HPV expression profile similar to the integration-
negative tumors. Although elevated levels of E6 and E7 proteins
are considered essential for development of the HPV-associated
malignant phenotype (12, 50), our observations raise the ques-
tion of whether, in some cases, HPV infection and subsequent
integration can drive tumorigenesis because of HPV-induced
perturbations of the host genome independent of the activities of
E6 and E7. Such a possibility could be illustrated by the tumor
that showed significant amplification and overexpression of the
NR4A2 oncogene without evidence of elevated E6 or E7 expres-
sion. Our studies suggest that the actions of HPV in the process of
tumorigenesis likely extend beyond the expression of viral onco-
proteins (at least in a subset of HNSCCs) and suggest a more
nuanced role for the virus than the conventional view of E6/E7-
mediated transformation by disruption of predominantly the TP53
and CDKN2A/RB1 axes. It may also be the case that the high
prevalence of HPV infection worldwide compared with HPV-
driven cancers is explained by a requirement for additional
genomic events downstream of HPV infection to drive tumor
formation. Although many host genome alterations, most notably
PI3K pathway mutations, have been shown to be enriched in
HPV-positive HNSCCs and cooperate in oncogenesis (14, 51), our
study suggests that additional interactions of HPV itself with the
host genome are likely to be relevant in the oncogenic process.
Although the use of preventative HPV vaccines has gained trac-
tion worldwide, we believe that attention should be also focused
on the development of therapeutic HPV vaccines for individuals
with HPV-driven HNSCCs, which is currently being explored by
the Stand Up to Cancer Initiative (www.standup2cancer.org) and
other investigators.
We observed the occurrence of integration breakpoints across
the entire viral genome; only in E1 gene, however, there were
more breakpoints than would have been expected by chance
(Fig. S2B). Sites of integration in the tumor genome were non-
random, suggesting that there is likely to be selection for par-
ticular clones within a tumor based on sites of HPV integration
that drive a survival and/or proliferation advantage, and we ob-
served that the molecular architectures of tumors with integrated
and nonintegrated HPV are likely distinct. Comparison with a
recent study in cervical cancer (52) revealed some similarities,
with HPV integration events targeting RAD51B, NR4A2, and
TP63. In addition, several HPV integration sites seem to be
unique to each dataset, but these differences may result from
the fact that the cervical cancer data were mainly derived from
transcriptome sequencing as opposed to the WGS data in this
study. It is likely that the size of our cohort is limiting in this
analysis, and we believe that a much larger cohort of HPV-
driven HNSCCs will need to be studied to fully account for
patterns of integration, address recurrence of integration in key
genes, and understand implications of integration on the biology
and pathogenesis of HPV-driven HNCs and the association with
clinical outcomes.
Distinct host genome methylation and expression patterns in
HPV integration-positive and -negative HNSCCs are additional
findings that may shed some new light on the possible mechanisms
by which HPV infection could facilitate or drive carcinogenesis in-
dependent of integration. Here, we present data describing a small
number of differentially methylated and expressed genes in tumors
with integrated and nonintegrated HPV, including IRX4 and SIM2,
genes that have shown roles in cancer biology (53). However, this
hypothesis requires additional exploration to establish the roles of
these genes and others that display distinct methylation and ex-
pression profiles in HPV-positive tumors with and without HPV
integration.
Our study, using DNA sequencing, RNA-seq, and DNA meth-
ylation data, highlights previously undescribed roles of HPV in
primary HNCs beyond production of the E6 and E7 viral onco-
proteins and suggests that HPV is likely to drive HNCs through
a variety of mechanisms, including expression of E6 and E7, in-
tegration in key cancer-related genes, changes in global DNA
methylation and gene expression, and facilitation of genomic in-
stability. Our study also provides evidence for increased sensitivity
of next generation sequencing methods for HPV detection com-
pared with p16 immunohistochemistry or HPV FISH and shows
evidence of HPV in tumors with atypical clinical features, such as
larynx origin or a background of heavy tobacco use. Given that
HPV status is used for risk stratification for patients undergoing
therapy for HNSCC, we feel that it is important to continue to
refine methods for HPV detection to both better enable preclinical
studies of the role of HPV in HNSCCs and provide accurate in-
formation to clinicians who are treating patients with HNSCCs.
Materials and Methods
The presence of HPV and its integration into tumor genome was detected
using WGS (30–60×, n = 28 and 6–8×, n = 122), RNA-seq, whole-exome se-
quencing, and molecular approaches (a PCR-based MassArray Assay, p16
staining, and HPV in situ hybridization). A subset of samples (n = 129), which
lacked evidence of HPV on the basis of RNA-seq, was not analyzed by WGS.
Both human and HPV gene expressions were assessed using the Illumina
TrueSeq protocol and Illumina HiSeq sequencers, with a target coverage of
60 million read pairs. Whole-genome methylation was assayed using the
Infinium HM4501 array. CNV was analyzed using the Bayesian Information
Criterion-sequencing algorithm.
Full methods and any associated references are available in SI Materials
and Methods.
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